| Document |
Document Title |
|
WO/2010/126170A1 |
Disclosed is a method for producing 3,4-dichloro-5-cyanoisothiazole represented by formula (3), comprising reacting a nitrile compound represented by general formula (1) (wherein n represents an integer of 0 to 2) with sulfur chloride re...
|
|
WO/2010/122968A1 |
Disclosed is a compound useful as an anti-obesity agent. Studies have been made on compounds which have a DGAT1 inhibitory activity and are therefore promising active ingredients for pharmaceutical compositions for treating obesity, type...
|
|
WO/2010/113857A1 |
Provided is a microbicide having 5-chloro-2-methyl-4-isothiazolin-3-one as the active component and a reduced amount of residual materials and hydrolysates from the organic solvents used in the industrial manufacturing method thereof. Th...
|
|
WO/2010/100139A1 |
The object of the present invention is benzothiazine derivatives having the capability of inhibiting 11β-HSD1 not only at an enzymatic level but also at a cell level. The compounds of the present invention are of general formula (I). Wh...
|
|
WO/2010/091543A1 |
The present invention relates to novel hydrazino-cyclobut-3-ene-1,2-dione compounds of Formula (I) as selective CXCR2 antagonists, pharmaceutical compositions containing the novel compounds, as well as methods for treating or preventing ...
|
|
WO/2010/092180A1 |
The present invention relates to aminotetraline derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminotetraline derivatives, and the use of s...
|
|
WO/2010/086118A1 |
The present invention relates to isothiazolyloxyphenyl amidines of the general formula (I), to a method for the production thereof, to the use of the amidines according to the invention for combating undesired microorganisms, and to an a...
|
|
WO/2010/083442A1 |
Disclosed are compounds of Formula (1), in which A1, Z1, Z1A, Z2, Z2A, L1 and Z3 are as defined in the claims, which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and their use in treating d...
|
|
WO/2010/079443A1 |
The present invention relates to compounds of the formula (I) and pharmaceutically acceptable salts, solvates or tautomers therof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing...
|
|
WO/2010/070615A1 |
Compounds of the formula I wherein R1a is H; and R1b is C1-C6 alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and R2b are H, halo, C1-C4alkyl, C1-C4haloalkyl, C1-C4alkoxy; or R2...
|
|
WO/2010/054926A1 |
A compound of the formula I or where W, X and Y are for example each CH; R1 is H; R2 is halogen; and R6 is, for formula I, for example, OH, CN, C3-C8-cycloalkyl, C3-C8-cycloalkyl-C1 -C6-alkyl, C2-C6-alkenyl, C2-C6-haloalkenyl, C2-C6-alke...
|
|
WO/2010/054024A2 |
The present application relates to isothiazolylidene containing compounds of Formula (I) wherein R1, R2, R3, R4, and L are as defined in the specification, compositions comprising such compounds, and methods for treating conditions and d...
|
|
WO/2010/044371A1 |
A sweet taste receptor agonist such as acesulfame K, sucralose, saccharin or glycyrrhizin can be used as an active ingredient for an insulin secretion stimulator. A candidate substance for an insulin secretion stimulator can be screened...
|
|
WO/2010/041748A1 |
Disclosed is a prophylactic or therapeutic agent for diabetes, diabetic complications, insulin resistance syndrome, metabolic syndrome, hyperglycemia, dyslipidemia, atherosclerosis, heart failure, cardiomyopathy, myocardial ischemia, cer...
|
|
WO/2010/039545A2 |
Novel classes of 1,2-benzisothiazolinone and isoindolinone compounds and compositions are disclosed. These compounds and compositions are useful in treating, preventing, and/or ameliorating viral, yeast, and fungal infections such as, fo...
|
|
WO/2010/034982A1 |
Provided are certain benzothiazole, imidazothiazole, imidazopyrimidine and imidazopyridine compounds, including, for example:formula (I) and pharmaceutically and physiologically acceptable salts, hydrates, and solvates thereof. Such comp...
|
|
WO/2010/024772A1 |
The invention provides compounds of the formula (I wherein Q is trifluoromethyl, C3-C6cycloalkyl, phenyl, p-fluorophenyl, pyridyl, thiazolyl, furyl, thienyl or C3-C6cycloalkylethynyl; R3 is C1-C6alkyl; R4 is C1-C6alkyl; W is cyano or flu...
|
|
WO/2010/008081A1 |
Disclosed is an azo pigment which has excellent color characteristics such as coloring power and hue, while exhibiting excellent durability such as light resistance. A pigment dispersion is also disclosed. Specifically disclosed is an a...
|
|
WO/2010/003025A1 |
The invention relates to bicyclic heterocycles of formulae I and II with anti-cancer and/or anti-inflammatory activity and more specifically with MEK kinase inhibitory activity. The invention provides compositions and methods useful for ...
|
|
WO/2009/101082A9 |
The present invention relates to the use of substituted sulfonic acid amide compounds of formula I, wherein Ra, n, Het, A, Y and D are as defined in the claims and the N-oxides and the salts thereof for combating phytopathogenic harmful ...
|
|
WO/2009/145286A1 |
Disclosed is a compound represented by formula (I) (wherein the symbols are as defined in the description), a salt thereof or the like.
|
|
WO/2009/141305A1 |
A compound of Formula (I) or Formula (II) where W is C-R3; X is C-R4; Y is C-R5; R1 and R6, independently of each other, is, for example, H, C1 -C6-alkyl, C2-C6-alkenyl, C2-C6- alkynyl, C3-C8-cycloalkyl or C1 -C6-alkyl-C(=O); R2 is H; an...
|
|
WO/2009/141065A2 |
The invention relates to a method for controlling animal pests, whereby (1,2-benzisothiazol-3-yl)(thio)carbamates and (1,2-benzisothiazol-3-yl)(thio)oxamates and the oxidation forms thereof of formula (I), wherein A, R1, R2, R3, R4, n, X...
|
|
WO/2009/114744A1 |
Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof, are disclosed, wherein J1, J2, B, Y, A and D are as described. Methods, compositions, and medicaments related thereto are also disclosed.
|
|
WO/2009/077362A1 |
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof:(formula) wherein: R1 represents optionally substituted C1-4 alkyl; X represents -(CR10R11 )n- in which n represents 1 or 2; R2, R3 an...
|
|
WO/2009/079593A1 |
The present invention is directed to piperidinyl and piperazinyl derivatives of formula (I) useful as inhibitors of the NPY Y2 receptor, pharmaceutical compositions comprising said compounds, processes for the preparation of said compoun...
|
|
WO/2009/076454A2 |
Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone...
|
|
WO/2009/067600A2 |
The present invention relates to a genus of biaryl compounds containing at least one further ring. The compounds are PDE4 inhibitors useful for the treatment and prevention of stroke, myocardial infarct and cardiovascular inflammatory di...
|
|
WO/2009/061652A1 |
Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating ...
|
|
WO/2009/056069A1 |
A successive preparation method of the 3-isothiazolone derivates and their intermediates. This method includes four successive steps, that is sulfuration, purification, amination and chlorination. Comparing with the intermission method d...
|
|
WO/2009/017813A1 |
The invention provides the saccharin salt of O-desmethyl venlafaxine, and a crystalline polymorph thereof. The invention also provides processes for the preparation of the saccharin salt, pharmaceutical formulations containing this salt,...
|
|
WO/2009/013122A2 |
The present invention relates to disperse azo dyes based on a phthalimido-substituted aniline coupling component and an aromatic-carbocyclic or an aromatic-heterocyclic diazo component, to a process for the preparation of such dyes and t...
|
|
WO/2009/011276A1 |
A zinc salt of an isothiazolone compound represented by the following formula (1); a method of stimulus reduction which comprises converting an isothiazolone compound represented by the formula (1) into a zinc salt; an antibacterial/anti...
|
|
WO/2009/012312A1 |
Compounds that inhibit Aurora-kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.
|
|
WO/2008/157802A1 |
This invention provides compounds of Formula (I), which are inhibitors of Chk2 and are useful as a radiation protection agents in anticancer radiotherapy. A method of modulating Chk2 in vitro includes treating a substrate with Chk2 in th...
|
|
WO/2008/154484A1 |
Compounds which directly inhibit IRE-lα activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be us...
|
|
WO/2008/142376A1 |
This invention pertains generally to the field of therapeutic compounds, and more particularly, to certain bicyclosulfonyl acid (BCSA) compounds which act as inhibitors of Tumour Necrosis Factor-α Converting Enzyme (TACE). The compounds...
|
|
WO/2008/136382A1 |
Disclosed is a compound represented by the following formula: (wherein R1 presents an optionally substituted hydrocarbon group, an optionally substituted amino group, an optionally substituted hydroxy group or an optionally substituted h...
|
|
WO2007139645B1 |
The present invention provides novel antimicrobial immobilized 1,2- benzisothiazolin-3-one/zinc oxide (BIT/ZnO) complexes useful as antimicrobial agents because of their resistance to being leached from the substrate to which they are at...
|
|
WO/2008/130953A2 |
The present application relates to isothiazolylidene containing compounds of Formula (I) wherein R1, R2, R3, R4, and L are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and di...
|
|
WO/2008/126772A1 |
Disclosed is a novel therapeutic agent for prehypertension or hypertension, which has a different xanthine oxidase inhibitory activity from that of a conventional hypotensive agent used in clinical practice, and which is more effective c...
|
|
WO/2008/123469A1 |
Disclosed is a compound having excellent SCD1 activity inhibitory action. Specifically disclosed is a compound represented by the general formula [B-0'] below, a pharmaceutically acceptable salt thereof, or a solvate thereof. [B-0'] (In ...
|
|
WO/2008/101976A1 |
A compound of general formula (I) : A process for preparing this compound. A fungicidal composition comprising a compound of general formula (I). A method for treating plants by applying a compound of general formula (I) or a composition...
|
|
WO/2008/102908A1 |
Disclosed is a novel herbicide. Specifically disclosed is a haloalkylsulfonanilide derivative represented by the general formula (1) below, or an agrochemically acceptable salt thereof. (In the formula, Q represents -N(R5)SO2R6, wherein ...
|
|
WO/2008/103185A2 |
This application relates to a substituted carboxamide compound of formula I, or a pharmaceutically acceptable salt thereof, as defined herein, a pharmaceutical composition thereof, and its use in treating pain.
|
|
WO/2008/090048A2 |
The invention provides 3-amino-1,2-benzisothiazole compounds of formula (I) wherein n, R1, R2, R3, R4 and A are defined as in the description. The invention provides further agricultural compositions comprising an amount of at least one ...
|
|
WO/2008/077188A1 |
The present invention provides a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment or prophylaxis of a viral infection in a subject comprising administer...
|
|
WO/2008/078674A1 |
Disclosed is a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof, wherein a carbon atom having an asterisk has an R-configuration; R1 and R2 independently represent a hydrogen atom, a halogen atom, an ...
|
|
WO/2008/057775A2 |
A compound of Formula I and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula I, and methods of treating conditions associated with th...
|
|
WO/2008/044767A1 |
Disclosed is a novel SCD inhibitor. The SCD inhibitor comprises a compound represented by the formula [I], a salt thereof, or a prodrug of the compound or the salt. wherein the ring A represents an aromatic ring which may be substituted;...
|
